行情

VERU

VERU

VERU
NASDAQ

实时行情|Nasdaq Last Sale

4.190
+0.090
+2.20%
盘后: 4.200 +0.01 +0.24% 17:09 01/17 EST
开盘
4.100
昨收
4.100
最高
4.210
最低
4.010
成交量
25.81万
成交额
--
52周最高
4.350
52周最低
1.180
市值
2.73亿
市盈率(TTM)
-22.0759
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VERU 新闻

  • 英国诺丁汉市开始试验无线充电的出租车
  • TechWeb.6小时前
  • 英财政大臣:脱欧后 英国“不会与欧盟结盟”
  • 中国新闻网.6小时前
  • FBI探员力挺苹果:已经为调查提供足够帮助
  • 新浪科技.6小时前
  • 亚马逊手掌支付进行终端测试 Visa等成合作伙伴
  • 新浪科技.7小时前

更多

所属板块

制药
+0.13%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

VERU 简况

Veru Inc. is an oncology and urology biopharmaceutical company developing medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals. Its oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase II clinical trial for the treatment of hot flashes in men, and VERU-100, which is a gonadotropin-releasing hormone (GnRH) antagonist. Its urology specialty pharmaceutical drug candidate is Tadalafil and Finasteride Combination (TADFIN), which is a tadalafil and finasteride combination oral capsule for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal Condom for prevention of pregnancy and sexually transmitted infections, and PREBOOST wipes for the prevention of premature ejaculation.
展开

Webull提供Veru Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。